Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 2/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.61 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.55 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115373 | 1.00 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL14532997 | 1.00 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL13777726 | 1.00 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL13296262 | 1.00 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL10459063 | 0.91 | ADORA2A (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL15462103 | 0.87 | ADORA3 (0.77) | AHCYADORA3HSP90B1ADORA2AADORA2B | |
| SCHEMBL19423461 | 0.87 | ADORA3 (0.77) | AHCYADORA3HSP90B1ADORA2AADORA2B | |
| SCHEMBL12359604 | 0.86 | ADORA2A (0.57) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL30712751 | 0.86 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL9404167 | 0.86 | AHCY (0.69) | AHCYHIF1ATMEM97SIGMAR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222228-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-07-17 | — | — | US | disclosed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-7671191-B2 | Methods for preparing 2-alkynyladenosine derivatives | PGX HEALTH, LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7605143-B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADENOSINE THERAPEUTICS, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7378400-B2 | Method to reduce an inflammatory response from arthritis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-04 | — | — | US | disclosed |
| US-7214665-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060100169-A1 | Method to reduce an inflammatory response from arthritis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-05-11 | — | — | US | disclosed |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100169-A1 | Method to reduce an inflammatory response from arthritis | PDE4A, PDE4B, PDE7A | AHCY 344/4885HIF1A 1125/4885TMEM97 4153/4885 |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | AHCY 887/4885HIF1A 1685/4885TMEM97 477/4885 |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADORA2A, ADORA3, ADORA1 | AHCY 116/4885HIF1A 2759/4885TMEM97 2809/4885 |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | AHCY 1970/4885HIF1A 2528/4885TMEM97 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.